Description: Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paclical/Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications. It also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for mammary carcinoma and squamous cell carcinoma; and Doxophos Vet for lymphoma. Oasmia Pharmaceutical AB was founded in 1988 and is based in Uppsala, Sweden.
Home Page: www.vivesto.com
Gustav III:s Boulevard 46
Solna,
169 73
Sweden
Phone:
46 18 50 54 40
Officers
| Name | Title |
|---|---|
| Dr. Christer Nordstedt M.D., Ph.D. | Acting Chief Exec. Officer |
| Mr. Robert Maiorana | Head of Accounting & Acting CFO |
| Mr. Kai Wilkinson | Chief Technical Officer |
| Dr. Reinhard Koenig | Chief Scientific Officer |
| Mr. Urban Ekelund | IR Mang. |
| Mr. John T. Cosby | Head of Regulatory Affairs |
| Mr. Dzianis Babrou | Head of Product Devel. |
| Mr. Henrik Rönnberg | Chief Medical Officer of Animal Health |
| Maria Nilsson Hagberg | Head of Regulatory Affairs |
| Ms. Johanna Rostin | Head of Regulatory Affairs |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6794 |
| Price-to-Sales TTM: | 31.1626 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 17 |